Trial reportJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
Effect of Huiyang Shengji unguent on the NOD-like receptor family pyrin domain containing protein 3/caspase1/ gasdermin D pathway and lymphatic angiogenesis in patients with diabetic foot ulcer.
Trial report in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo investigate the mechanism of Huiyang Shengji unguent (, HYSJ) for improving inflammation and promoting wound healing in patients with diabetic foot.
methodsThe primary components of the HYSJ unguent were analyzed using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). A total of 20 patients with a diabetic foot wound were divided randomly into either a HYSJ treatment group (10 cases) or control group (10 cases). The HYSJ group was treated for 14 d with Hui Yang Shengji unguent, while the control group was treated for 14 d with basic fibroblast growth factor unguent. Central granulation tissue and wound secretions were collected before treatment and on the 7th and 14th day, respectively. The proteins prospero homeobox protein 1 (PROX-1), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) and vascular endothelial growth factor receptor 3 (VEGFR-3) associated with lymphatic angiogenesis were detected by immunohistochemistry, the levels of inflammatory cytokines in wound exudates including interleukin-1β (IL-1β), interleukin-18 (IL-18), and vascular endothelial growth factor C (VEGF-C) were measured using enzyme-linked immunosorbent assay, while the protein levels of NOD-like receptor family, pyrin domain containing protein 3 (NLRP3), caspase-1, gasdermin D, and N-terminal gasdermin D were measured using immunoimprinting.
resultsUPLC-MS/MS analysis revealed that the high-abundance peak compounds in HYSJ unguent included coclaurine, glucoraphanin, citric acid, gallic acid, L-glutamine, and gentianose. Following treatment, there was a significant reduction in IL-1β and IL-18 levels in the HYSJ group's wound exudates on day 14 compared to pre-treatment values (
conclusionsThe mechanism of HYSJ to promote wound healing of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.